Evaluation of p53 Nuclear Accumulation in Low- and High-Grade (WHO/ISUP Classification) Transitional Papillary Carcinomas of the Bladder for Tumor Recurrence and Progression

Abstract

Objectives: To evaluate the association of p53 nuclear accumulation with recurrence and progression in transitional cell carcinomas of the bladder and to examine the distribution of p53 in low-grade and high-grade transitional cell carcinomas according to the World Health Organization/International Society of Urological Pathology classification. Patients and Methods: Nuclear accumulations of p53 were examined in a total of 99 patients with transitional cell carcinoma between May 1995 and October 1999. The mean age was 64 years. There were 94 (95%) men and 5 (5%) women. Following resection, surgical specimens were examined, and p53 accumulation with a 20% cutoff value was accepted as positive staining. Of the 99 patients, 52 (53%) had histologically superficial bladder tumors, and 47 (47%) had invasive tumors. Data concerning grade, stage, number of recurrences, and disease progression were available for each patient. Results: The median follow-up period was 55 months. 60 of the 99 patients (61%) had p53 overexpression. The difference for p53 overexpression between low-grade and high-grade tumors was significant (p < 0.05). In low- and high-grade tumors, there was no significant relationship for recurrence between p53-positive and p53-negative groups. But there was a statistically significant relationship between progression and histological grade of the tumors. p53 had no significant relationship with tumor recurrences (p > 0.05), but its relationship with progression was statistically significant (p < 0.05). Conclusions: We did not find a correlation between tumor recurrence and p53 overexpression, but p53 overexpression has a predictive value in determining tumor progression. High-grade tumors had higher p53-positive values than low-grade tumors. This group of patients should be considered for radical therapies on the basis of other prognostic parameters.

The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder

“…The expression of p53 was nuclear in all tumor tissues, which confirms previous observations [12]. There was no correlation between p53 expression and any of the clinicopathologic characteristics recorded.…”

“…The mutant p53 also has a longer half-life. Therefore, nuclear p53 protein accumulation is a common phenomenon in many human malignancies [12][13][14], and for that reason we selected it as a second marker in this study.…”

Immunohistochemical Evaluation of Vascular Urinary Bladder Tumors from Cows with Enzootic Hematuria

“…Mutations of p53 occur in 50% of human cancers, 22,51 including softtissue angiosarcoma, 27,50 and usually lead to p53 protein accumulation in the nucleus.…”

Expression of Vascular Endothelial Growth Factor, Receptor KDR and p53 Protein in Transitional Cell Carcinoma of the Bladder

“…Mutated p53, together with other factors, can induce cell transformation and accelerate tumor growth and metastasis. The half-life of the mutant form of the p53 protein is enhanced from 6 to 20 min to several hours and accumulation of p53 protein in the nucleus of cancer cells has been observed [8] . Recent studies have shown that there were correlations between p53 protein and VEGF expression in some tumors, indicating the involvement of p53 in tumor angiogenesis [9,10] .…”